Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Olpasiran on QT/QTc Intervals in Healthy Subjects
NCT06411860Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised trial of olpasiran in cardiovascular disease (CVD) (4 arms), sponsored by Amgen. Primary endpoint: Placebo-corrected Change From Baseline in QT Corrected for Heart Rate (HR) Interval Based on the Fridericia Correction. Started Sep 2024; status: completed.
02
Drugs
olpasiran
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT06411860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411860.